• JoomlaWorks Simple Image Rotator
  • JoomlaWorks Simple Image Rotator
  • JoomlaWorks Simple Image Rotator
  • JoomlaWorks Simple Image Rotator
  • JoomlaWorks Simple Image Rotator
  • JoomlaWorks Simple Image Rotator
  • JoomlaWorks Simple Image Rotator
  • JoomlaWorks Simple Image Rotator
  • JoomlaWorks Simple Image Rotator
  • JoomlaWorks Simple Image Rotator
 
  Bookmark and Share
 
 
Doctoral Thesis
DOI
10.11606/T.5.2004.tde-11082005-150129
Document
Author
Full name
Mônika Conchon Ribeiro de Mello
E-mail
Institute/School/College
Knowledge Area
Date of Defense
Published
São Paulo, 2004
Supervisor
Committee
Llacer, Pedro Enrique Dorlhiac (President)
Almeida, Therezinha Verrastro de
Bendit, Israel
Chauffaille, Maria de Lourdes Lopes Ferrari
Velloso, Elvira Deolinda Rodrigues Pereira
Title in Portuguese
"Avaliação da resposta clínica e citogenética em portadores de leucemia mielóide crônica, tratados com inibidor da tirosina quinase (imatinib)"
Keywords in Portuguese
ANÁLISE CITOGENÉTICA
CROMOSSOMO PHILADELPHIA
ESTUDOS DE AVALIAÇÃO
INTERFERON ALFA/uso terapêutico
LEUCEMIA MIELÓIDE CRÔNICA/fisiopatologia
LEUCEMIA MIELÓIDE CRÔNICA/genética
LEUCEMIA MIELÓIDE CRÔNICA/terapia
PROTEÍNA TIROSINA QUINASE/uso terapêutico
SEGUIMENTOS
Abstract in Portuguese
O STI (imatinib, Glivec) é um inibidor da tirosina quinase BCR-ABL, responsável pela patogênese da leucemia mielóide crônica (LMC). Um total de 110 pacientes com LMC na fase crônica (FC) que falharam ou foram intolerantes ao tratamento com interferon, fase acelerada (FA) e crise blástica (CB) foram tratados com imatinibe entre dezembro de 2000 e setembro de 2003. Resposta hematológica completa e resposta citogenética maior foram observadas em 95,9% e 69,4% respectivamente em pacientes em FC e 93,2% e 36,4% em FA. Apenas 2 pacientes na CB estão vivos. O imatinib foi bem tolerado com altas taxas de resposta.
Title in English
Hematologic and cytogenetic response in chronic myeloid leukemia patients treated with inhibitor of tyrosine kinase (imatinib)
Keywords in English
CYTOGENETIC ANALYSIS
EVALUATION STUDIES
FOLLOW UP STUDIES
INTERFERON ALPHA/therapeutic use
LEUKEMIA MYELOID CHRONIC/genetics
LEUKEMIA MYELOID CHRONIC/physiopathology
LEUKEMIA MYELOID CHRONIC/therapy
PHILADELPHIA CHROMOSOME
PROTEIN TYROSINE KINASE/therapeutic use
Abstract in English
STI571 (Imatinib, Glevec) is an inhibitor of the Bcr-Abl tyrosine kinase that is central to the pathogenesis of chronic myelogenous leukemia (CML). A total of 110 patients with CML chronic phase (CP) who failed or were intolerant to interferon, accelerated phase (AP) and blastic crisis (BC) were treated with imatinib from December 2000 until September 2003. Complete hematologic response and major cytogenetic response were observed in 95,9% and 69,4% respectively of patients in CP and 93,2% and 36,4% in AP. Only 2 patients are alive in BC. Imatinib is well tolerated with high rates of response
 
WARNING - Viewing this document is conditioned on your acceptance of the following terms of use:
This document is only for private use for research and teaching activities. Reproduction for commercial use is forbidden. This rights cover the whole data about this document as well as its contents. Any uses or copies of this document in whole or in part must include the author's name.
Monikaconchon.pdf (1.29 Mbytes)
Publishing Date
2005-08-11
 
WARNING: Learn what derived works are clicking here.
All rights of the thesis/dissertation are from the authors
Centro de Informática de São Carlos
Digital Library of Theses and Dissertations of USP. Copyright © 2001-2020. All rights reserved.